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.V. This is an open access article und1. Introduction: A Decade-old Cytokine
In 2005, Schmitz et al. identiﬁed interleukin-33 (IL-33), a 30 kDa nu-
clear cytokine that belongs to the IL-1 family (Schmitz et al., 2005) and
that acts as an “alarmin” in response to the cellular damage induced by
stress or by infection (Cayrol and Girard, 2014, Moussion et al., 2008).
IL-33 is constitutively expressed within the nucleus of endothelial ander the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
38 V. Mehraj et al. / EBioMedicine 9 (2016) 37–44of epithelial cells, particularly in tissue barrier sites and in ﬁbroblastic
reticular cells of the lymph nodes and of the spleen, in which this cyto-
kine contributes to the maintenance of mechanical barriers (Moussion
et al., 2008, Martin and Martin, 2016, Schmitz et al., 2005, Peine et al.,
2016, Cayrol and Girard, 2014). Furthermore, IL-33, which is released
by damaged endothelial and epithelial cells at barrier sites, functions
as a damage-associated molecular pattern (DAMP) to trigger activated
T-cells, either indirectly through proinﬂammatory cytokine production
by innate immune system cells, or directly in a TCR-independent man-
ner by binding to pattern recognition receptors (PRRs) on T-cells, as re-
cently reviewed (Peine et al., 2016). T-cells can also directly respond to
IL-33 via its cognate suppressor of tumorigenicity 2 (ST2) receptor
(Smithgall et al., 2008, Peine et al., 2016). IL-33 mainly targets mast
cells, basophils, dendritic cells (DCs), macrophages, natural killer (NK)
cells, group 2 innate lymphoid cells (ILC2) and T helper 2 (Th2) cells,
all of which express ST2 (Jovanovic et al., 2012, Martin and Martin,
2016, Miller, 2011). The ST2 receptor to which the biologically active
formof IL-33 binds is a complex consisting of the full-length, transmem-
brane isoform of ST2 (ST2L), in association with the IL-1 receptor acces-
sory protein (IL-1rap); this receptor complex is expressed at barrier
sites and also on certain peripheral blood mononuclear cells including
the mast cells, NK cells and Th2 cells (Martin and Martin, 2016,
Molofsky et al., 2015a). Conversely, the extracellular IL-33 that is re-
leased following cell damage is cleaved in a caspase-dependent and -in-
dependent manner, and also undergoes extracellular cysteine
oxidation, all of which reduce the efﬁcacy and half-life of IL-33. Howev-
er, some isoforms of full length extracellular IL-33 and spliced variants
of mature IL-33 still possess biological activity (Villarreal and Weiner,
2015, Cayrol and Girard, 2014, Cayrol and Girard, 2009). Moreover,
the activity of extracellular IL-33 is controlled by its binding to theFig. 1. Schematic representation of the induction of the IL-33/ST2 axis and its role in innate a
epithelial cells and can undergo cleavage/splicing by enzymes secreted by mast cells and by n
to induce inﬂammatory and tissue healing effects. The induction of ST2 expression by CD4 and
the functions of the IL-33/ST2 axis. Abbreviations: MΦ: macrophage; DC: dendritic cell; ILC2
tumorigenicity2; sST2: soluble ST2; Treg: regulatory T-cell.soluble form of ST2 (sST2), which serves as a decoy receptor to locally
limit ‘off target’ IL-33 activity, thus avoiding inappropriate inﬂammato-
ry responses (Kakkar and Lee, 2008) Fig. 1.
IL-33 was originally found to play a role in innate immunity and in
the Th2 response involved in tissue repair following allergic reactions
and helminthic infections (Lu et al., 2015). It is now known that IL-33
is also a crucial costimulator in the adaptive immune response, amplify-
ing the responses of antiviral cytotoxic T lymphocytes (CTLs); IL-33 thus
acts as an adjuvant (Villarreal et al., 2015b). Furthermore, Schiering et
al. have shown that in mice, ST2 is preferentially expressed on colonic
Treg cells, thereby allowing IL-33 to promote Treg function by inducing
transforming growth factor (TGF)-β1-mediated differentiation of these
cells in an inﬂammatory environment (Schiering et al., 2014).
More recently, IL-33 was shown to enhance the differentiation pro-
grams of diverse T-cell subsets including Th1, Th2, and Treg cells via the
induction of their respective master regulator transcription factors T-
bet, GATA-3 and Foxp3, in addition to inducing their speciﬁc signal
transducer and activator of transcription (STAT) proteins (Peine et al.,
2016). Furthermore, IL-33was reported to amplify the inﬂammatory ef-
fects of differentiated Th1 and Th2 cell cultures in conjunction with IL-
18, another IL-1 family member (Blom and Poulsen, 2012, Samarani et
al., 2016).
In contrast to its constitutive expression on ILC2, Treg and Th2 cells,
ST2 expression on Th1 cells is transient and contributes to virus-speciﬁc
CD4 T-cell expansion, Th1 effector differentiation, and antiviral cytokine
production (Molofsky et al., 2015a, Schmitz et al., 2005). Baumann et al.
have shown that ST2 is induced on Th1 effector cells upon differentia-
tion both in vitro and in vivo following lymphocytic choriomeningitis
virus (LCMV) infection (Baumann et al., 2015). In Th1 cells, STAT4 and
T-bet cooperate to drive ST2 expression. The absence of ST2 on CD4 T-nd adaptive immune responses. Intracellular IL-33 is released by apoptotic and necrotic
eutrophils to generate the active form of IL-33. ST2 expressing cells are targeted by IL-33
CD8 T-cells results in their expansion and survival. An array of cytokines is implicated in
: group 2 innate lymphoid cells; Ag: antigen; IL-33: interleukin-33; ST2: suppressor of
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creased expansion, impaired effector function, and reduced T-cell–me-
diated immunopathology.
Molofsky et al. recently delineated the dynamic role of the IL-33/ST2
axis during microbial invasion with respect to the loss of epithelial in-
tegrity at damaged barrier sites (Molofsky et al., 2015b). Following an
acute infection causing tissue injury, IL-33 synergized with other epi-
thelial cytokines and chemokines to induce remodeling and to promote
tissue homeostasis and repair. However, during chronic infection, a
“conversion phase” occurs duringwhich amassive release of IL-33 over-
whelms the local regulation mediated by sST2, leading to an inﬂamma-
tory response that in turn promotes NK, Th1 and cytotoxic CD8 T-cell
responses (Bonilla et al., 2012, Molofsky et al., 2015a, Molofsky et al.,
2015b, Cao et al., 2016). Over time, this persistent inﬂammation during
chronic infection induces tissue damage and ﬁbrosis (Li et al., 2014a).
The IL-33/ST2 axis has been reported to play a role in an increasing
number of conditions associated with either tissue necrosis, as in the
case of cardiac insufﬁciency and atherosclerosis (Miller et al., 2008,
Miller, 2011), or with breached barriers as in the case of asthma (Li et
al., 2014a, Salter et al., 2016), graft vs. host disease (GVHD)
(Reichenbach et al., 2015, Vander Lugt et al., 2013), biliary cirrhosis
(Volarevic et al., 2012, Sun et al., 2014), ulcerative colitis (UC) and Crohn's
disease (CD) (Pastorelli et al., 2010). A role for the IL-33/ST2 axis has also
been reported in autoimmune diseases such as systemic lupus erythema-
tosus (SLE) (Li et al., 2014b) and rheumatoid arthritis (RA) (Tang et al.,
2013), and in different allergic conditions (Cayrol and Girard, 2014,
Hayakawa et al., 2007, Nygaard et al., 2016, Salter et al., 2016). Plasma
levels of sST2, which are an indirect measure of IL-33 activity, have been
used to predict disease outcome and/or to monitor treatment response
in a number of conditions including cardiac insufﬁciency and colitis
(Andersson et al., 2016).More recently, the IL-33/ST2 axiswas implicated
in septic shock (Alves-Filho et al., 2010), and in infections with Dengue
virus (Becerra et al., 2008), Toxoplasma gondii (Jones et al., 2010), and
Pseudomonas aeruginosa (Hazlett et al., 2010).
Collectively, these lines of evidence suggest that the IL-33/ST2 axis
plays a key role in inducing tissue repair when barriers are breached,
by alarming and enhancing immune responses in diverse conditions in-
cluding cardiac insufﬁciency, autoimmune conditions, colitis, and
infections.
The molecular and cellular roles of the IL-33/ST2 axis in animal and
in human health and disease have been recently reviewed (Jovanovic
et al., 2012, Cayrol and Girard, 2014, Rostan et al., 2015, Peine et al.,
2016). Herein, we highlight the dynamic role of the IL-33/ST2 axis in
the innate and adaptive immune responses that occur during acute
and chronic infections, with a focus on HIV, hepatitis B and C viruses
(HBV and HCV) and cytomegalovirus (CMV). We also discuss the IL-
33/ST2 axis as a potential therapeutic target.
2. HIV Infection and the IL-33/ST2 response: Sounding the Alarm
Given that IL-33 is rapidly released from damaged cells following tis-
sue damage, necrosis and activation of the inﬂammasome (Martin and
Martin, 2016), it has been suggested that IL-33 may play a role in the
pathogenesis of HIV infection (Barouch et al., 2016). In 2011, Miyagaki
et al. were the ﬁrst to report elevated sST2 levels in HIV-infected patients
and in uninfected patients with skin barrier damage due to atopic derma-
titis, compared to healthy controls (Miyagaki et al., 2011). Additionally,
they observed reduced plasma levels of IL-33 in HIV-infected patients in-
dependently of the severity of their infection, in contrast to patients with
atopic dermatitis. However, the dysregulated plasma levels of sST2 and of
IL-33 did not correlate with age, eosinophil count or with other clinical
parameters, which could be due to the small sample size of the study. In
contrast, Secemsky et al. reported that 332 long-term antiretroviral ther-
apy (ART)-treatedHIV-infectedpatients had similar sST2 levels compared
to age- and sex-matched controls (Secemsky et al., 2015). The aim of this
study was to assess and to compare plasma sST2 levels with novelcardiovascular disease biomarkers such as growth differentiation factor
15 (GDF-15) and troponin I, in addition to established biomarkers such
asC-reactive protein (CRP), D-dimer, IL-6 and cystatin C (Table 1). Despite
non-elevated ST2mean levels, sST2 and GDF-15were predictors of cardi-
ac insufﬁciency and of all-causemortality in ART-treated patients, consis-
tent with previous reports of uninfected individuals (Chen et al., 2013).
Furthermore, Fitch et al. recently reported elevated ST2 levels as amarker
of myocardial ﬁbrosis in asymptomatic HIV-infected patients (Fitch et al.,
2016). However, it should be noted that in both of these studiess of treat-
ed, HIV-infected individuals, single cross-sectional assessments of each
biomarker were made.
HIV-associated gut barrier dysfunction and immune activation,
which have been observed to occur early in infection, represent inde-
pendent predictors of morbidity and mortality (Ponte et al., 2016,
Hunt et al., 2014). The initiation of ART during chronic infection can re-
duce, but not normalize, barrier dysfunction and immune activation
(Ananworanich et al., 2015, Hunt et al., 2014). We and others have re-
ported that when ART is initiated immediately following HIV infection,
plasma levels of gut damage markers remain elevated, in contrast to
markers of cellular activation and of inﬂammation, which decrease sig-
niﬁcantly (Jenabian et al., 2015, Ananworanich et al., 2015). Our pro-
spective analysis failed to detect a signiﬁcant reduction in sST2 levels
in patients initiating ART during the early phase of HIV infection,
while long-term treatment initiated during the chronic phase normal-
ized sST2 levels (Mehraj et al., 2016). Importantly, we determined the
alarmin contribution of the IL-33/ST2 axis to the immune response by
reporting a correlation of elevated sST2 levels with the CD8 T-cell
count and with T-cell activation in the absence of a correlation with
the plasma viral load. Thus, the immune response following acute infec-
tion characterized by increased numbers of CD8 T-cells and increased
activation of these cells was associated with elevated sST2 levels, in re-
sponse to ‘the alarm’. The elevated sST2 levels correlated with
indoleamine 2,3-dioxygenase enzyme activity and IFN-γ levels, both
of which are implicated in Th1/Th2 regulation. Our ﬁndings in HIV-in-
fected individuals support those reported by Baumann et al. of a murine
lymphocytic choriomeningitis virus (LMCV) model in which IL-33 in-
duced and enhanced Th-1 responses (Baumann et al., 2015). Further-
more, during acute HIV infection, sST2 levels correlated with the levels
of intestinal fatty acid binding protein (I-FABP) and of sCD14, markers
of gut epithelial damage and of microbial translocation, respectively.
These observations establish a link between sST2 and gut tissue dam-
age. Interestingly, these associationswere lost during chronic HIV infec-
tion, suggesting a phase-dependent and transient role for the IL-33/ST2
axis in disease progression (Fig. 2).Moreover, IL-33, in conjunctionwith
long-term TGF-β stimulation, has been shown to be associatedwith the
development of ﬁbrosis in a murinemodel of bleomycin-induced ﬁbro-
sis (Li et al., 2014a). Gao et al. recently showed that in amurinemodel of
diet-induced nonalcoholic steatohepatitis, IL-33 treatment prevented
steatosis, while inducing ﬁbrosis, in a ST2-dependent manner (Gao et
al., 2016). Furthermore, in patients with either chronic obstructive pul-
monary disease or with idiopathic pulmonary ﬁbrosis, IL-33 is involved
in the induction of lung ﬁbrosis in bronchial epithelial cells via the in-
duction of IL-6 and IL-8 (Shang et al., 2015). It is well established that
during the chronic phase of HIV infection, collagen deposition in lym-
phoid tissues including Peyer's patches in the gut disrupts the T-cell
zone and limits the number of resident CD4 T-cells (Schacker et al.,
2005). The development of ﬁbrosis is an important issue given that
the level of lymphatic tissue collagen deposition foretells themagnitude
of CD4 T-cell recovery following ART initiation. Thus, after sounding the
alarm, the IL-33/ST2 axis may contribute to the development of ﬁbrosis
during the chronic phase of HIV infection (Fig. 2).
Collectively, these ﬁndings suggest a role for ST2 in HIV pathogene-
sis; this process is probably driven by HIV-induced damage to gut epi-
thelial cells during the early, asymptomatic phase of infection. These
ﬁndings also suggest that ST2 might be used as a surrogate marker of
Th1 cell activation. More research is needed to conﬁrm a direct link
Table 1
Studies assessing IL-33/ST2 dysregulation in the context of human infection with HIV, HBV and HCV.
Ref. Infection Tissue/organ/methods Sample size (n) Principal ﬁndings on IL-33/ST2
axis
Correlations/associations with IL-33/ST2 axis Comments
Miyagaki
et al.
(2011)
HIV Serum
ELISA
26→ HIV;
28→ AD;
21→ C
sST2 levels increased but IL-33
levels decreased in HIV patients.
No correlation of sST2 or IL-33 with age,
eosinophil count or other clinical measurements.
First report of
IL-33/ST2 in HIV
infection
Yndart
et al.
(2015)
HIV Cell culture and in
vitro infection ELISA
qPCR,
WB caspase assay
3 independent
experiments
HIV-1 clade B
causes increases in
IL-33/ST2L expression
IL-33/ST2 expression led to increased
expression of inﬂammatory genes and
apoptosis in neuronal cells.
No such associations
with HIV-1 clade C
infection.
Secemsky
et al.
(2015)
HIV Serum biomarkers
and ECG andmortality
data
332→ HIV
50→ C
ST2 and GDF-15 independently
predicted cardiovascular
dysfunction and all-cause
mortality.
ST2 was the only factor predictive of diastolic
dysfunction.
ST2 was not elevated in
chronic HIV infected
patients.
Mehraj
et al.
(2016)
HIV Plasma and PBMCs
ELISA FC qPCR
153→ HIV (48
EHI, 61 CHI, 23
CHI-ART, 21 EC)
20→ C
sST2 plasma levels were
elevated in early HIV infection
independent of age, sex, BMI,
creatinine, cholesterol and CRP
levels.
sST2 correlated with markers of gut damage,
microbial translocation and immune activation.
No such associations
were found in chronic
HIV infection. IL-33
levels were not
modulated.
Marvie
et al.
(2010)
HBV/HCV Human liver biopsies,
mice liver ﬁbrosis
model,
qPCR, cell
culture, ELISA,
WB, IHC
34→ HCC
6→ C
IL-33 and ST2 mRNA levels
increased in ﬁbrotic liver in
humans and mice
IL-33 correlated with ST2.
IL-33 correlated with collagen synthesis in liver.
Endothelial and stellate cells were the major
sources of IL-33.
T-cell expressed ST2.
IL-33/ST2 levels in HCC
were similar to
controls.
Wang
et al.
(2012a)
HBV Serum and in vitro
infection assays,
ELISA, CBA
33→ CHB
20→ C
IL-33 and sST2 serum levels
increased in CHB at the baseline.
IL-33 levels did not correlate with AST and ALT.
IL-33 was associated with viral DNA inhibition
in vitro.
No correlation between sST2 and IL-33 levels.
IL-33 levels decreased
with 12 weeks of
adefovir dipivoxil
therapy
Lei et al.
(2015)
HBV Serum, liver biopsies,
ELISA, IHC
48→ ACLF
12→ CHB
16→ C
sST2 but not IL-33 was increased
in HBV-ACLF
sST2 levels did not correlate with IL-33, TNF-α,
IFN-γ and IL-10.
sST2 levels predicted
disease severity and
mortality
Gao et al.
(2015)
HBV Serum ELISA 60→ ACLF-HBV
58→ CHB
30→ C
IL-33 and ST2 serum levels were
elevated in patients with HBV
associated ACLF.
In ACLF-HBV, IL-33 levels signiﬁcantly
correlated with ALT levels, while sST2 levels
signiﬁcantly correlated with total bilirubin,
HBV viral load and model for end-stage liver
diseases. Elevated sST2 levels also predicted
poor survival.
In all participants,
serum IL-33 was
signiﬁcantly
correlated with sST2.
Wang
et al.
(2012b)
HCV Serum ELISA, CBA 154→ CHC
24→ SR-HCV
20→ C
IL-33 and sST2 serum levels
increased in CHC
IL-33 levels correlated with AST and ALT in CHC
No correlation between sST2 and IL-33 levels
IL-33 levels decreased
with 12 weeks of IFN
therapy
Abbreviations: HIV = Human immunodeﬁciency virus; HBV= hepatitis B virus; HCV= hepatitis C virus; AD= atopic dermatitis; IL-33 = interleukin-33; GDF-15 = growth differenti-
ation factor 15; PBMCs = peripheral blood mononuclear cells; EHI = Early HIV Infection; CHI = chronic HIV infection; ART = antiretroviral therapy; EC = Elite controller; BMI = body
mass index; CRP=C-reactive protein; CHC= chronic hepatitis C; SR-HCV= spontaneously resolvedHCV; C= controls; HCC=hepatocellular carcinoma; CHB= chronic hepatitis B; IFN
= interferon; ELISA = Enzyme-linked immunosorbent Assay; CBA = Cytometric Bead Array; WB =Western Blot; ECG: Echocardiograms; ALT = alanine aminotransferase; AST =
aspartate aminotransferase; ACLF = acute on chronic liver failure; IHC = Immunohistochemistry; FC = ﬂow cytometry; qPCR= quantitative polymerase chain reaction.
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and with the Th1 response ex vivo, in HIV infection, as observed in the
murine LCMV model (Liang et al., 2015).
Upregulation of the IL-33/ST2 axis in the central nervous system
(CNS) has also been reported to be associated with neurocognitive
changes in HIV infection (Yndart et al., 2015). Speciﬁcally, IL-33 overex-
pressionwas associatedwith decreased synaptic function, increased ap-
optosis, and neuroinﬂammation in HIV-1 clade B infected CNS cell
cultures. These results further support a role for dysregulation of the
IL-33/ST2 axis in HIV infection.
IL-33 and IL-18, anothermember of the IL-1 family, are both processed
by the inﬂammasome (Petrasek et al., 2012). Inﬂammasomes, the signal-
ing platforms that detect pathogenic microorganisms and sterile
stressors, are activated via protease caspase-1, IL-1β and IL-18 (two pro-
inﬂammatory cytokines), and to a lesser extent, via IL-33 (Latz et al.,
2013). Importantly, HIV-1 infection and inﬂammasome assembly are at
play sincemanypathogen-associatedmolecular patterns (PAMPs) are de-
rived from the virus' envelope, capsid, RNA, and reverse-transcribedDNA.
The PAMPs and DAMPs produced by the destruction of infected CD4 T-
cells and of damaged gut epithelial cells activate several pattern recogni-
tion receptors (PRRs) that include toll like receptors (TLRs), C-type lectin-
like receptors (CLRs), RIG-like receptors (RLRs) and node-like receptors
(NLRs), all of which contribute to the activation of transcription factors,
such as NF-kB, that induce the expression of type-1 interferons, pro-inﬂammatory cytokines such as IL-1β and IL-18, and chemokines. HIV
also activates different NLRs which results in the assembly of an
inﬂammasome, the activation of caspase-1, and in the processing and re-
lease of IL-1 family cytokines (Samarani et al., 2016).
The contribution of the inﬂammasome to early SIV pathogenesis
have been recently identiﬁed in necropsy studies of rhesus monkeys;
these studies revealed that components of the inﬂammasomewere trig-
gered by SIV both at the site of inoculation and at early sites of distal
virus spread as soon as 24 h post-infection (Barouch et al., 2016). We
and others have previously shown increased levels, compared to
healthy controls, of serum IL-18 inHIV-infected individuals; these levels
were inversely correlated with the numbers of various NK cell subsets
(Ahmad et al., 2002, Iannello et al., 2009); these cells express ST2 and
are also targets of IL-33. A recent study of amurinemodel of CMV infec-
tion showed that NK cell expansion was mediated by ST2, with beneﬁ-
cial anti-viral effects (Nabekura et al., 2015). Thus, the individual and
potential synergistic effects of IL-18 and of IL-33 at tissue barrier sites
and in the blood warrant further investigation.
3. The IL-33/ST2 Axis in Viral Hepatitis: Creating Damage by Inducing
Liver Fibrosis
Imbalances in the Th1/Th2 response were ﬁrst implicated in the
pathogenesis of hepatic failure induced by acetaminophen, mushroom
Fig. 2. IL-33/ST2 axis plays a dual role in gut epithelial homeostasis and immune activation during chronic viral infections. This ﬁgure depicts HIV infection as amodel of acute and chronic
phases of infection. A: During acute HIV infection, PAMPs and epithelial gut damage lead to the release of IL-33 which acts as a DAMP to alert the immune system. Expression of IL-33
receptor ST2 is increased on a number of lamina propria immune cells. Such immune activation contributes to the imbalance in Th1/Th2/Treg ratios. Soluble ST2 is released into the
peripheral blood, which correlates with the markers of gut damage and of immune activation. B: During chronic HIV infection, epithelial gut damage extends with persistent IL-33
secretion and immune activation. IL-33 and TGF-β contribute to the tissue ﬁbrosis. CD4 T-cells gradually decrease in the periphery and the plasma sST2 levels decline in comparison to
the acute phase. Abbreviations: PAMPs = pathogen associated molecular patterns; DAMP = damage associated molecular pattern; MΦ=macrophage; DC = dendritic cell; ILC2 =
group 2 innate lymphoid cells; IL-33 = interleukin-33; ST2 = suppressor of tumorigenicity2; NK = natural killer cell; Th1 = T helper cell type 1; Th2 = T helper cell type 2; Treg:
regulatory T-cell.
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33/ST2 axis was shown to be upregulated in all of these cases of hepatic
failure.
Furthermore, adenovirus-induced hepatitis in mice, which caused
increased hepatic expression of IL-33 and of ST2,was associatedwith at-
tenuated liver injury, with an increase in Tregs, and with a decrease in
macrophage, DC, and NK cell tissue inﬁltration (Liang et al., 2013). The
same group recently showed in a murine LCMV infection model that
IL-33 deﬁciency resulted in a marked reduction in the number of IFN-
γ + γδ T and NK cells, and in an increased number of Th17+ γδ T-
cells, 16 h post-infection (Liang et al., 2015). These changes were re-
versed by treatment with recombinant IL-33, which induced DC prolif-
eration and cytokine production.
Recent studies have explored the contribution of the IL-33/ST2 axis
to the pathology caused by HBV and HCV (Lei et al., 2015, Liang et al.,
2013, Wang et al., 2012a, Roth et al., 2010, Gao et al., 2015) (Table-1).
Roth et al. ﬁrst reported signiﬁcantly elevated sST2 serum concentra-
tions in patients with hepatic insufﬁciency due to various infectious
and non-infectious causes (Roth et al., 2010). Signiﬁcant sST2 upregula-
tion was found in patients with acute liver failure or with acute-on-
chronic liver failure, compared to patients with chronic hepatic failure
(CHF) and to healthy controls. sST2 levels in CHFwere also signiﬁcantly
higher than in controls. The investigators also reported correlations be-
tween IL-33, sST2 and alanine aminotransferase (ALT) serum levels in
acute and in chronic liver failure. These results suggest that the IL-33/
ST2 axis is a modulator of immune activation/inﬂammation in liver fail-
ure, and that this axis could be used to differentiate different disease
stages.
Wang et al. reported higher IL-33 serum levels in patients with
chronic HBV infections compared to healthy controls; these levelsdecreased in response to a 12-week treatment with the anti-viral
adefovir dipivoxil (Wang et al., 2012a). Interestingly, serum sST2 levels
remained elevated in the chronically infected HBV patients who did not
respond to therapy, and these levels did not correlate with plasma IL-33
levels. These results suggest that sST2 is an early marker of acute liver
failure, while elevation of IL-33 is linked to the development and to
the progression of liver ﬁbrosis. The same group also reported higher
IL-33 levels in patientswith chronic HCV infection compared to patients
who spontaneously cleared infection or to healthy controls. They also
showed that serum IL-33 levels correlated with serum aspartate trans-
aminase (AST) levels in chronically infected HCV patients (Wang et al.,
2012b). Furthermore, the IL-33 level decreased after 12 weeks of inter-
feron treatment; this observation is consistentwith the decreased levels
of IL-33 observed in adefovir dipivoxil-treated patients with chronic
HBV infection (Wang et al., 2012a). Finally, the elevated levels of sST2
observed in the studies of HCV and of HBV patients did not correlate
with IL-33 levels, nor did the sST2 levels decrease with treatment.
These ﬁndings suggest that IL-33 and ST2 contribute to the hepatic
damage caused by HBV and HCV infections. Gut epithelial damage
with microbial translocation also appears to play a role in inducing the
hepatic damage that occurs in HBV and HCV infections.
Lei et al. showed higher sST2 levels with nodifference in IL-33 levels,
in HBV patients with acute-on-chronic liver failure, compared to con-
trols and to patients with chronic HBV infection (Lei et al., 2015).
These increased sST2 levels correlated with disease severity and pre-
dicted poor survival. At the cellular level, Marvie et al. showed an asso-
ciation between IL-33 and ST2 overexpression in the liver and in the
development of hepatic ﬁbrosis due to chronic infections with HBV or
HCV, and due to alcoholic hepatitis (Marvie et al., 2010). This study
also revealed that hepatic stellate cells and sinusoidal endothelial cells
42 V. Mehraj et al. / EBioMedicine 9 (2016) 37–44are themain sources of IL-33 during the development of liver ﬁbrosis in
both mice and humans.
Collectively, these various lines of evidence suggest an important
role for the IL-33/ST2 axis in the development of ﬁbrosis in chronic in-
fectious hepatitis. Large-scale prospective studies are required to assess
the validity of the IL-33/ST2 axis as a predictor of disease progression,ﬁ-
brosis and survival compared to other, currently used markers such as
the AST-to-platelet ratio index, the ﬁbrosis-4 (FIB-4) score, and more
expensive, non-invasive tests, such as elastography and the FibroTest
(Stasi and Milani, 2016).
4. The Contribution of the IL-33/ST2 Axis to Herpes Infections
IL-33 expression is induced in DCs, monocytes/macrophages and
mast cells in response to inﬂammation (Arshad et al., 2016). Aoki et al.
recently showed in a murinemodel that mast cell stimulation of herpes
simplex virus 2 (HSV2)-infected keratinocytes induced increased IL-33
production (Aoki et al., 2013). They further showed that blocking ST2
on bone marrow-derived mast cells signiﬁcantly inhibited their ability
to produce TNF-α and IL-6. Interestingly, Oh et al. have shown in a mu-
rine model of mucosal HSV2 infection that the dysbiosis caused by oral
antibiotic treatment directly impaired antiviral immune response, thus
leading to defective immune protection (Oh et al., 2016). They also
showed that after the depletion of commensal local microbiota, IL-33
secretion from vaginal epithelium inhibited effector T-cell migration
to vaginal tissue and blocked the local production of IFN-γ. These ﬁnd-
ings indicate that antiviral defense mechanisms are regulated in part
by IL-33 viamicrobial dysbiosis, whichmay be relevant for the develop-
ment of HSV2 prophylactic strategies.
Cytomegalovirus (CMV), another member of herpesviradae family,
causes latent infection in humans (Gianella et al., 2015). The signaling
role of the IL-33/ST2 axis in the NK cell response during CMV infection
in mice was reported by Nabekura et al. They showed in a murine
model of MCMV infection that ST2-deﬁcient Ly49H+NK cells were im-
paired in their ability to drive MCMV-speciﬁc expansion of naïve cells
into memory cells. Furthermore, when re-challenged with MCMV, IL-
18R signaling was required for the secondary expansion of memory
Ly49H+NK cells. These ﬁndings suggest that IL-33 is released by dam-
aged cells in the early phase of MCMV infection and that ST2 signaling
transiently enhances MyD88 signaling to augment the proliferation of
naive and memory Ly49H+ NK cells (Nabekura et al., 2015).
5. The Combined Effect of HIV and Co-infections on the IL-33/ST2
Axis
To date, studies assessing the effects of various viruses on the IL-33/
ST2 axis have involved mono-infected animals or humans, as discussed
above. It is expected that in the case of co-infections, viruses will
synergize to enhance the IL-33 response. Studies involving co-infected
animals and humans will be required to test this hypothesis.
6. The Therapeutic Potential of the IL-33/ST2 Axis
There have been increasing efforts to develop a vaccine and a cure
for HIV infection (Routy et al., 2016). Knowing the critical role played
by the T-cell response in host defense, these strategies mainly focus
on inducing effective Th1 and cytotoxic CD8 T-cell responses, although
strategies that induce beneﬁcial antibody responses are also being in-
vestigated. The use of molecules acting as DAMPs, including IL-33, as
vaccine adjuvants that enhance Th1 potency has gained considerable at-
tention in recent years (Villarreal and Weiner, 2015, Villarreal et al.,
2014, Villarreal et al., 2015a). Unlike other peptide-adjuvant conjugates
that directly activate antigen presenting cells (APCs) through pattern
recognition pathways, an IL-33-boosted vaccine was shown to activate
NKT-cells via severalmechanisms, resulting in an indirect enhancementof APC function in a murine model of allergic airway inﬂammation
(Anderson et al., 2014).
A few animal studies have been conducted inwhich IL-33was tested
as an adjuvant in vaccines against various pathogens. An intranasal vac-
cine containing recombinant inﬂuenza virus hemagglutinin and IL-33
induced elevated, inﬂuenza-speciﬁc plasma IgG levels, mucosal inﬂuen-
za-speciﬁc IgA, and increased expression of both Th1 and Th2–related
cytokines, all of which led to the protection of the challenged mice
that received this vaccine; in contrast, control mice whose vaccines
did not contain IL-33 adjuvant were not protected (Kayamuro et al.,
2010). In a murine LCMV model, Villarreal et al. reported an increase
in the magnitude and in the function of antigen-speciﬁc CD8 T-cells
upon immunization with a DNA vaccine coadministered with IL-33
(Villarreal et al., 2015b). Antigenic re-stimulation led to the expansion
of these polyfunctional cytotoxic cells in vivo,which conferred efﬁcient
protection against a lethal dose of LCMV. The IL-33 adjuvant also en-
hanced potent HIV-speciﬁc responses in a vaccine setting. Moreover,
IL-33 co-administration led to increased numbers of effector CD8 T-
cells compared to the administration of vaccine alone.
A few animal studies have also shown the beneﬁts of IL-33 in differ-
ent models of infection. For example, Bonilla et al. showed in a murine
model of LCMV infection that the IL-33 released by necrotic cells en-
hanced the activation and the clonal expansion of ST2+ CD8+ T lym-
phocytes, resulting in a LCMV-speciﬁc cytotoxic response (Bonilla et
al., 2012). Other investigators used recombinant IL-33 in amurine inﬂu-
enzamodel to reduce lung impairment (Monticelli et al., 2011),while in
amurine coxsackie B virusmodel of experimental pancreatitis, IL-33 in-
duced the production of IFN-γ and TNF-α by CD8+ T and by NK cells,
resulting in viral clearance (Sesti-Costa et al., 2013).
We have shown that in early HIV infection, sST2 levels are elevated
(Mehraj et al., 2016). These sST2 levels correlated with the CD8 T-cell
count, with immune activation and with microbial translocation, sug-
gesting that sST2 is a marker of gut damage and of disease progression.
Interestingly, no such associations were observed in patients with
chronic HIV infection. As the roles of IL-33 and ST2 in viral infections
are phase-dependent, therapeutic strategies need to be rationally de-
signed according to each phase. Therefore, blockade of sST2 should be
of therapeutic value during the acute phase, while blockade of IL-33
should be considered for the chronic phase (Okragly et al., 2016)
when ﬁbrosis develops in lymphoid tissues or in the liver. Further stud-
ies of the regulation of the intracellular and cytoplasmic expression of
IL-33 during tissue damage in the gutwill be required in order to devel-
op therapeutic interventions, with a focus on epithelial cells, ILC2 and
other cells that express the ST2 receptor.
7. Future Directions
The mechanisms linking IL-33-mediated T-cell proliferation and/or
survival to cytokine production will beneﬁt from further in vivo studies.
The interaction of IL-33 with other IL-1 family members, such as IL-18,
needs to be thoroughly investigated to identify potential synergistic ef-
fects that may further contribute to an adjuvant effect. Follicular helper
T-cells (Tfh cells) are an important subset of T-cells that are involved in
the formation and in the maintenance of germinal centers of secondary
lymphoid organs where B cells mature and produce antibodies (Kerfoot
et al., 2011); it remains unknown whether ST2 is expressed on Tfh cells.
The expression of ST2 on Tfh cells could have important implications for
vaccination by potentially contributing to the maturation of the antibody
response by neighboring B cells, a process that requires CD4 T cell help.
A better understanding of the regulation of the transcription factors
currently known to control ST2 expression, such as T-bet, GATA-3 and
STATs, and of CTL-regulating transcription factors, will also be critical
for the design of novel immunotherapies that target the IL-33/ST2
axis. The identiﬁcation of other sources of sST2 beyond ILC2s, Th2 and
Tregs, which may explain the dynamics of the IL-33/ST2 axis in various
conditions, will also be required.
43V. Mehraj et al. / EBioMedicine 9 (2016) 37–448. Concluding Remarks
Data from animal models and from a limited but increasing number
of human studies have shed considerable light on the involvement of
the IL-33/ST2 axis in various inﬂammatory conditions and in the patho-
genesis of diseases including acute and chronic viral infections. The pro-
tective and destructive functions of this axis may eventually allow for
the development of axis-speciﬁc therapies that vary according to the
type, phase and/or location of the infection. Translational studies involv-
ing blood and damaged tissues will be required to further elucidate the
roles of the IL-33/ST2 axis in infection and in immunity so that novel im-
munotherapeutic approaches can be designed to reduce inﬂammation
and to contribute to vaccine and cure strategies for the various diseases
to which this axis contributes.
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